Delivery Order SPE2DB20D6037-SPE2DB24FTXH9

Award Date 9/27/24
Potential Completion Date 9/30/24
Potential Value $4.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,217.16 firm fixed-price delivery order is for the supply of Alfuzosin Hydrochloride Extended-Release 10 mg Tablets in 120-count bottles. The contract is part of a larger indefinite delivery contract (IDC) with the DLA valued at up to $499,999,999, which allows the agency to issue delivery orders...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,449.52, is for the delivery of Alfuzosin Hydrochloride Extended-Release 10 mg tablets. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,844.60 contract is for the delivery of Alfuzosin Hydrochloride, a pharmaceutical product, with a completion date of March 21, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This federal contract award, valued at $5,603.19, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Alfuzosin HCL ER 10 mg tablets, a medication used to treat benign prostatic hyperplasia. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued...
This is a delivery order (SPE2DB24D6039|SPE2DB24FLDYT) awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, Corporate Office Division, a major pharmaceutical distributor. The $1,190.17 firm-fixed-price contract is for the supply of Alfuzosin HCL ER 10 mg tablets. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for providing a comprehensive range of medical...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,699.40 firm-fixed-price delivery order is for 4,566,716,754 units of Alfuzosin HCl ER 10 mg tablets, with a completion date of December 16, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
DMS Pharmaceutical Group Inc. has been awarded a firm fixed price delivery order for $1,673.32 under an indefinite delivery contract with the Defense Logistics Agency to supply alfuzosin hydrochloride. The delivery order was awarded on August 30, 2022 with a completion date of September 9, 2022. DMS Pharmaceutical Group will provide the pharmaceutical item to Defense Logistics Agency Troop Support Medical facilities located in Park Ridge, Illinois. DMS Pharmaceutical Group is a woman-owned small...
This federal contract award, identified as SPE2DB22D3004|SPE2DB25FPS90, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,513.70 firm fixed-price delivery order contract is for the supply of 4,567,416,944 units of the drug Alfuzosin HCl ER 10 mg Tablet. The award is not designated as a set-aside contract. It is associated with a larger Indefinite Delivery Contract (IDC) held by...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and federal contractor. The $2,086.06 firm-fixed-price contract is for the supply of 120 tablets of Alfuzosin HCL ER 10 mg, a medication used to treat benign prostatic hyperplasia. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Alfuzosin HCL ER 10 mg tablets. The contract is a firm fixed price, non-set-aside award with a ceiling value of $1,466.08 and a performance period ending on April 29, 2025. Amerisourcebergen Drug Corp is the prime contractor for this delivery order, which is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB20D6037
    Indefinite Delivery Contract
  • SPE2DB20D6037-SPE2DB24FTXH9
    Delivery Order

This federal contract award, valued at $4,227.15, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of Alfuzosin HCL ER 10 mg tablets to fulfill the recurring medical supply needs of military health facilities.

The award is a firm fixed-price delivery order under DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999 and running through December 31, 2025. This IDC allows the DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support the diverse medical requirements of the Department of Defense (DoD) healthcare system. As a prime vendor, DMS Pharmaceutical Group provides both routine and critical medications to military personnel and their dependents across various DoD facilities. The contract does not have a set-aside designation.

Generated 12/27/24, 9:12 AM